News
Best wishes from our entire IBA RadioPharma Solutions team!
Best wishes from our entire IBA RadioPharma Solutions team!
See more
AlF-peptides labelling method - One process to label them all…
IBA intend to propose commercial kits for AlF-peptide process on Synthera®+ (IFP, reagents, ancillaries)
See more![[18F]F-rhPSMA-7.3](https://hm-offload.s3.eu-west-3.amazonaws.com/iba/2024/12/PSMA-1.jpg)
18F-flotufolastat (previously known as 18F rhPSMA-7.3)
Automated labeling of flotufolastat gallium triflutate with 18F on the IBA Synthera®+ Platform - a simplified and efficient approach
See more
[18F]FES /16α-[18F]-fluoroestradiol
[18F]luoroestradiol / [18F]FES /16α-[18F]-fluoroestradiol. Radiolabeled analog of estradiol used as a contrast agent in the PET imaging of estrogen receptor-positive breast cancer lesions.
See more
IBA Reports Third Quarter 2024 Results
IBA, the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, today announces its business update for the third quarter 2024.
See moreAlmathera selects IBA to equip Kazakhstan’s first private radiopharmacy and theranostics complex with Cyclone® KIUBE 300
Almathera selects IBA to equip Kazakhstan’s first private radiopharmacy and theranostics complex with Cyclone® KIUBE 300
See more
Rigging of the Cyclone® IKON at CNRT in China
Successful rigging of the 2ⁿᵈ worldwide IBA high-energy cyclotron, Cyclone® IKON, in Chengdu, Sichuan, China
See moreIBA partners with Jubilant Radiopharma, selling five Cyclone® KIUBE to support their PET radioisotope production across the US
IBA partners with Jubilant Radiopharma, selling five Cyclone® KIUBE to support their PET radioisotope production across the US
See moreIBA and Jules Bordet Institute to lead IHI project Accelerate.EU to create complete Astatine-211 value chain
IBA, the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, today announces its business update for the first quarter ending 31 March 2024.
See more